Dasolampanel

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameDasolampanel
Drug Alias Name达兰帕奈dasolampanelum达索帕奈NGX-426LY-545694
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate receptor ionotropic AMPA antagonistsKainic acid receptor antagonists
TargetsKainic acid receptorGlutamate receptor ionotropic AMPA
Therapy Area/IndicationsDiabetic NeuropathiesHyperalgesiaOsteoarthritis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesRomaniaPuerto Rico +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And CompanyTorreypines Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsDiabetic NeuropathiesHyperalgesiaOsteoarthritis +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG